MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Vanda Pharmaceuticals Inc

Suletud

4.48 -2.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.44

Max

4.58

Põhinäitajad

By Trading Economics

Sissetulek

412K

-4.9M

Müük

5.5M

53M

Aktsiakasum

-0.084

Kasumimarginaal

-9.236

Töötajad

368

EBITDA

727K

-8.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+266.67% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

63M

315M

Eelmine avamishind

7.09

Eelmine sulgemishind

4.48

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2024, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet

2. apr 2024, 22:59 UTC

Suurimad hinnamuutused turgudel

Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder

Võrdlus sarnastega

Hinnamuutus

Vanda Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

266.67% tõus

12 kuu keskmine prognoos

Keskmine 16.5 USD  266.67%

Kõrge 20 USD

Madal 13 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Vanda Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 4.74Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.